IE43267B1 - 1-/ -(r-thio)phenethyl/imidazoles and derivatives thereof - Google Patents

1-/ -(r-thio)phenethyl/imidazoles and derivatives thereof

Info

Publication number
IE43267B1
IE43267B1 IE2061/75A IE206175A IE43267B1 IE 43267 B1 IE43267 B1 IE 43267B1 IE 2061/75 A IE2061/75 A IE 2061/75A IE 206175 A IE206175 A IE 206175A IE 43267 B1 IE43267 B1 IE 43267B1
Authority
IE
Ireland
Prior art keywords
imidazole
phenethyl
compound
substituted
acid addition
Prior art date
Application number
IE2061/75A
Other versions
IE43267L (en
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of IE43267L publication Critical patent/IE43267L/en
Publication of IE43267B1 publication Critical patent/IE43267B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Abstract

The novel imidazole derivatives correspond to the formula in which R, R<1> and p have the meanings given in Patent Claim 1, and m is 0, 1 or 2. To prepare the compounds of formula I, wherein m is 0, a compound of formula: is reacted with a compound of formula RSH. X denotes a group which can be split off. To prepare compounds of formula I, wherein m represents 1 or 2, a) a compound of formula II is reacted with a compound of formula RSH and b) the resulting compound of formula I, wherein m represents O, is oxidised. m conforms to the conditions specified for q in Patent Claim 7. The compounds of formula I are obtained in the form of their free base or of its acid addition salts. These can be converted into one another. An agent for inhibiting the growth of fungi or bacteria in plants or in agricultural or industrial products contains a compound of formula I as active ingredient, mixed with a carrier. The compounds of formula I possess, quite generally, an antifungal and antibacterial action and can also be used for pharmaceutical purposes.

Description

The present invention relates fco novel imidazole derivatives and more particularly to 1-[(3-(R-thio) phenethyl] imidazoles, 1-[β-(R-sulfinyl)phenethyl]imidazoles and 1-[(3’(R-sulfonyl)phenethyl]imidazoles having the formula (I) and the addition salts thereof, wherein: R is alkyl, alkenyl, aralkenyl, substituted aralkenyl, alkynyl, cycloalkyl, cycloalkyl alkyl, aralkyl, substituted aralkyl, aryl or substituted aryl, said substituted aralkenyl and substituted aralkyl containing at least one substituent on the aryl moiety selected from the group consisting of halo, lower alkyl, lower alkoxy, trifluoromethyi, nitro and cyano and said substituted aryl containing at least one substituent selected from the group consisting of halo, lower alkyl, lower alkoxy, trifluoromethyi, nitro, amino, acylamino and cyano; R^ is hydrogen, halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro, cyano, thiocyanato the group CO) n 2 in which R2 is alkyl, cycloalkyl, aralkyl, substituted aralkyl, aryl θ', substituted aryl, said substituted aralkyl and said substituted aryl containing at least one substituent on the aryl lttoiety selected from the group consisting of halo, lower alkyl, lower alkoxy, trifluoromethyi, nitro and cyano; -24 I 43367 m, n and p are independently selected from the integers zero, 1 and 2; . provided that: the value of m cannot be greater than the value of n 5 except when R is aryl or substituted aryl.
The term alkyl as used in the specification and appended claims refers to a saturated, unbranched or branched acylic hydrocarbon group containing 1 to 20 carbon atoms inclusive, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, i-butyl, t-butyl, n-pentyl, n-heotyl, n-octyl, n-nonyl, ndodecyl, n-octadecyl and the like. The term lower alkyl refers to an alkyl group as previously defined containing 1 'to 6 carbon atoms, inclusive. The term lower alkoxy refers to groups of the formula lower alkyl-Owherein the lower alkyl substituent is as previously defined.
The term cycloalkyl as used herein refers to a saturated, monocyclic hydrocarbon group having 5 to 8 ring carbon atoms, such as cyclopentyl, cyclohexyl, cycloheptyl and the like.
The term cycloalkyl alkyl refers to a cyeloalkyl group as previously defined attached to an unbranched acyclic hydrocarbon group containing 1 to 3 carbon atoms, such as cyclopentylpropyl, cyclohexylmefchyl, cyclohexylethyl, cycloheptylmethyl and the like. The term alkenyl refers to an unbranched or 'branched acyclic hydrocarbon group having carbon-carbon double bond and containing 2 to 12 carbon atoms such as allyl, 2-hexenyl, 3-octenyl, 2-octenyl, 2-decenyl and the like. 343267 The term aralkenyl refers to a hydrocarbon moiety in which the alkenyl portion containing 2 to 4 carbon atoms is attached to a hydrocarbon group consisting of one or more aromatic rings and containing 6 to 10 ring carbon atoms such as 3phenyl-2-propenyl, 4-pheny1-3-butenyl, styryl, 3-naphthyl-2propenyl and the like. The term alkynyl refers to an unbranched or branched acyclic hydrocarbon group having carboncarbon triple bond unsaturation and containing 2 to 12 carbon atoms, such as 2-propynyl, 3-hexynyl, 2-octynyl and the like. The term aryl refers to a hydrocarbon group consisting of one or more aromatic rings and containing 6 to 10 ring carbon atoms, such as phenyl and naphthyl. The term aralkyl refers to a hydrocarbon moiety in which the alkyl portion contains 1 to 4 carbon atoms and the aryl portion is defined as above. Representative examples of aralkyl groups include benzyl, 3-phenylpropyl and the like. The term acylamino, i.e., R-C(O)-NH-, refers to substituents containing up to 12 carbon atoms, wherein R in such substituents is methyl, ethyl, i-propyl, n-butyl, pentyl, octyl and the like. The term halo as used herein refers to chloro, fluoro and bromo. The term acid addition salts refers to salts of the subject compounds formed with inorganic acids such as hydrochloric acid/ hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid and the like, or organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, maionic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic aci'd, ethanesulfonic acid, ptoluenesulfonic acid, salicylic acid and the like. -443267 All compounds of Formula (I) possess at least one chiral center, i.e., the carbon atom to which are attached the (R^)p RS (0) moieties.
Accordingly, the compounds of the present invention may be prepared in 5 either optically active form, or as a racemic mixture.
Unless otherwise specified, the compounds described herein are all in the racemic form. However, the scope of the subject invention herein is not to be considered limited to the racemic form, but to encompass the individual optical isomers of the subject compounds.
If desired, racemic intermediates or final products prepared herein may be resolved into their optical antipodes by conventional resolution means known per se, for example, as described in U.S. Patents 3,717,655 and 3,839,574 or by the separation (e.g., fractional crystallization) of the diastereomeric salts formed by reaction of, e.g., racemic compounds of Formula (I) with an optically active acid, or the diastereomeric esters formed by reaction of the racemic alcohol precursors of compounds of Formula (II) with an optically active acid.
Exemplary of such optically active acids are the optically active forms of camphor-10-sulfonic acid, a-bromo-camphor-πsulfonic acid, camphoric acid, menthoxy-acetic acid, tartaric acid, malic acid, diacetyltartaric acid, pyrrolidone-5-carboxylie acid, and the like. The separated pure diastereomeric salts or esters may then be cleaved by standard means to afford the respective optical isomers of the compounds of Formula (I) or the precursor alcohols. - 5 43267 A preferred subclass of compounds within the class defined by Formula (I) are those compounds having the formula hA \=/ iK1] CH—CH0I 2 s ί R and the acid addition salts thereof, wherein R, R^ and p are as defined above.
A preferred group of compounds within the above defined subclass are those wherein R^ is halo and R is alkyl, alkenyl, aralkenyl, halo substituted aralkenyl, aralkyl, halo substituted aralkyl, aryl and halo substituted aryl.
Particularly preferred compounds within the group described in the previous paragraph are those wherein [R1]ir is mono, halo or dihalo and R is alkyl containing 1 to 12 carbon atoms, 2-alkenyl, phenyl-2-alkenyl, chloro substituted pheny1-2-alkenyl, benzyl, chloro or fluoro substituted benzyl phenyl and chloro substituted phenyl. Most particularly preferred compounds are those wherein [R1] represents 2,4P dichloro, 2,4-dibromo or 2,4-difluoro.
The subject compounds of Formula (I) exhibit anti-fungal and anti-bacterial activity. For example, compounds of the present invention exhibit anti-fungal activity against human and animal pathogens such as Microsporum audouini, Microsporum gypseum, Microsporum gypseum - canis, Epidermophyton floccosum, Trichophyton mentagrophytesTrichophyton rubrum, Trichophyton tonsurans, - 6 43267 Candida albicans, and Cryptococcus neoformans.
The compounds of the present invention also exhibit anti-fungal activity against fungi of primarily agricultural importance such as Aspergillus' flavus, Cladosporium herbarum, Fusarium graminearum, Penicillium notatum, Aspergillus niger, Penicillium oxalicum, Penicillium spinulosum, and Pithomyces chartarum.
In addition, the compounds of the present invention exhibit anti-bacterial activity against human and animal pathogens, such as Staphylococcus aureus, Streptococcus faecalis, Corynebacterium acnes, Erysipelothrix insidiosa, Escherichia coli, Proteus vulgaris, Salmonella choleraesuis, Pasteurella multocida, and Pseudomonas aeruginosa. _ 7 „ In view of the aforementioned activities, the subject' compounds are found to be useful antimicrobials, having not only pharmaceutical but also agricultural and industrial application.
Accordingly, a further aspect of the present invention relates to compositions for pharmaceutical, agricultural, and industrial use, which compositions comprise the subject compouhds of Formula (I) in combination with a suitable carrier.
A still further aspect of the present invention relates to methods of inhibiting the growth of fungi and bacteria by applying to a host object containing, or subject to attack by, 'fungi or bacteria, a fungicidally or bacteriocidally effective amount of a compound of the present invention or a suitable composition containing same.
In pharmaceutical applications, compositions may be solid, semi-solid or liquid in form such as tablets, capsules, powders, suppositories, liquid solutions, suspensions, creams, lotions, ointments and the like. Pharmaceutically acceptable non-toxic carriers, or excipients normally employed for solid formulations include tricalcium phosphate, calcium carbonate, kaolin, bentonite, talcum, gelatin, lactose, starch and the like? for semisolid formulations there may be mentioned, for-example, polyalkylene glycols, vaseline and other cream bases; for liquid formulations there may be mentioned, for example, water, oils of vegetable origin and low boiling solvents such as isopropanol, hydrogenated naphthalenes and the like. The pharmaceutical compositions containing the compounds of the present invention may be subjected to conventional pharmaceutical expedients such as sterilization and can contain conventional pharmaceutical excipi30 ents such as preservatives, stabilizing agents, emulsifying agent! salts for the adjustment of osmotic pressure and buffers. The - 8 43287 compositions may also contain other therapeutically active materials. In pharmaceutical applications, the subject compounds and compositions may be administered to humans and animals by conventional methods, e.g., topically, orally, parenteraily and the like. When given orally the compounds, alone or in admixture with a suitable carrier, may be administered at a dosage of from about 12.5 mg. to about 1000 mg. per dose (assuming a 70 kg. host subject), one or more times daily,1 extending over a period of several days to many weeks. Suppositories may contain from about 1 mg. to 500 mg. of active compounds .
Topical application is preferred. For such treatment, an area having an existing fungal or bacterial growth, or to be protected against attack by fungi or bacteria, may be treated with the subject compounds or compositions by, for example, dusting, sprinkling, spraying, rinsing, brushing, dipping, smearing, coating, impregnating and the like. Pharmaceutical compositions containing the compounds of the present invention exhibit anti-fungal and anti-bacterial activity over a wide range of concentration, for example, from about 0.1 to 10.0% by weight of the composition. In any event, the composition to be administered will contain a quantity of the subject compound in an amount effective for relief or prevention of the specific condition being treated. The exact regimen for pharmaceutical administration of the compounds and compositions disclosed herein will necessarily be dependent upon the needs of the individual subject being treated, the type of treatment e.g., whether preventative or curative, the type of organism involved and, of course, the judgment of the attending practitioner. - 9 43267 In agricultural applications, the subject compounds may be applied directly to plants (e.g., seeds, foliage) or to soil. For example, compounds of the present invention may be applied to seeds alone or in admixture with a powdered solid carrier. Typical powdered carriers are the various mineral silicates, e.g mica, talc, pyrophyllite, and clays. The subject compounds may also be applied to the seeds - 10 43367 in admixture with a conventional surface-active wetting agent with or without additional solid carrier. Surface-active wetting agents that can be used are any of the conventional anionic, non-anionic or cationic types. As a soil treatment for fungi and the like, the subject compounds can be applied as a dust in admixture with sand, soil or a powdered solid carrier such as a mineral silicate with or without additional surface-active agent, or the subject compounds can be applied as an aqueous spray optionally containing a surface-active dis10 persing agent and a powdered solid carrier. As a foliage treatment, the subject compounds may be applied to growing plants as an aqueous spray which contains a surface-active dispersing agent with or without a powdered solid carrier and hydrocarbon solvents.
In industrial applications, the subject compounds may be used to control bacteria and fungi by contacting the pathogens with the compounds in any known matter. Materials capable of supporting bacteria and fungi may be protected by contacting, mixing or impregnating these materials with the subject com20 pounds. In order to increase their effect, the subject compounds may be combined with other pesticidal control agents such as fungicides, bactericides, insecticides, miticides and the like. A particularly important industrial/agricultural use for the subject compounds of the present invention is as a food preservative against bacteria and fungi which cause deterioration and spoilage of foods.
- II 43 267 Detailed Description The present invention, in a still further aspect, is directed to methods for the preparation of the subject compounds of Formula (I) according to the following reaction sequence: -.12 43267 RSH I \=/ + (I) I W CH SR .
(I-a) R (I-b) wherein R, R^ and p are as previously described and X represents a conventional leaving group such as chloro, bromo or a reactive ester group such as CHj-s(ο)2θ“ or p-CH^-CgH^-s(0)2~0-.
The 1-[β-(R-thio)phenethyl]imidazoles of Formula I-A are prepared by condensing a compound of Formula II with a thiol of Formula III.
In said condensation, the starting materials and reagents may be contacted in any convenient manner and maintained at a. temperature and for a period of time sufficient to complete the reaction. Furthermore, the reaction products may be isolated and recovered from the reaction using,as in the case of the reaction conditions - 13 43367 themselves, procedures conventional or known in the art for conducting such reactions or analogous reactions. The nature of the leaving group (X) is not critical, its selection being predicated on relative reactivity rates known for reactions of this ty > Chloro, bromo, and the two ester groups noted above are given by way of typical examples only.
Generally, the reaction of compounds of Formula II with compounds of Formula III wherein R in Formula III is alkyl, alken aralkenyl, substituted aralkenyl, alkynyl, cycloalkyl, cycloalkyl alkyl, aralkyl and substituted aralkyl is carried out in the presence of an inert organic solvent, e.g. tetrahydrofuran, ether menthanol and the like in the presence of sodium hydride or other suitable base at a temperature of 20 to 66°C for a period of 30 minutes to 24 hours.
The reaction of compounds of Formula II with compounds of Formula III wherein R in Formula III is aryl or substituted aryl is carried out in the presence of an inert organic solvent, e.g. acetone, methanol, and the like and in the presence of potassium carbonate or other suitable base under reflux conditions for a period of 30 minutes to 12 hours.
The thus obtained 1-[β-(R-thio)phenethyl]imidazole compounds of Formula I-A are then optionally oxidized to obtain the 1—[β— (R-sulfinyl)phenethyl]-and the 1-[β-(R-sulfonyl)phenethyl]imidazo compounds of Formulas I-B and I-C, respectively. Oxidation is conducted by methods well-known in the art using hydrogen peroxid an organic peracid such as peracetic acid, p-nitroperbenzoic aoi and m-chloroperbenzoic or an inorganic peracid such as periodic acid. The oxidation reaction is preferably conducted using mchloroperbenzoic in a liquid reaction medium, such as a ohlor0 inated hydrocarbon. - 14 43267 In said oxidation, the starting materials and reagents may be contacted in any convenient manner and maintained at a temperature and for a period of time sufficient to complete the reaction. Furthermore, the reaction products may be isolated and recovered from the reaction using, as in the case of the reaction conditions themselves, procedures conventional or known in the art for conducting such reactions or analogous reactions.
In general, when the compounds of Formula I-A are contacted with about one or more equivalents of oxidizing agent, such as m-chloroperbenzoic acid, at a temperature of from about -30°C to about 30°C, perferably in an organic medium, such as chloroform, and for a period of about 30 minutes to about 6 hours, the corresponding sulfinyl products of Formula I-B are obtained. Similarly, when the compounds of Formula I-A are contacted with about two or more equivalents of oxidizing agent, such as m-chloroperbenzoic acid, at a temperature of from about 0°C to about 60°C, preferably in an organic medium, such as chloroform, and for a period of about 1 to about 24 hours, ’ the corresponding sulfonyl products of Formula I-C are obtained. - 15 43267 The subject compounds of the instant invention can be isolated as free bases, however, since many of the compounds in base form are oils or gums, it is more convenient to isolate and characterize the compounds as acid addition salts. These salts are prepared in the usual manner, i.e., by reaction of the base compound with suitable inorganic or organic acid. Xf desired, the salts can be readily converted to the compounds in base form by treatment with alkali, such as potassium carbonate, sodium carbonate or sodium or potassium hydroxide..
The starting compounds of formula II, wherein R^ is hydrogen, methyl, methoxy, halo, nitro or lower alkyl sulfonyl are disclosed together with a method for their preparation in U.S. Patent 3,679,697. Compounds of Formula II wherein R4, is other than those groups disclosed in the above-identified paπ tent, with the exception of R*S(O)' -, can be analogously prepared, i.e., by bromination of the appropriate acetophenone, reaction of the resultant 2-bromo acetophenone compound with imidazole, reduction of the resultant 2-(1-imidazolyl)acetophenone compound with sodium tetrahydroborate, and finally, reaction of the resultant l-imi’dazoleethanol compound with a thionyl halide to yield the 1-(β-halophenethyl)imidazole compounds of Formula II. Compounds of Formula II wherein R1 is the group R S(o)_-are prepared by oxidation of corresponding compounds of Formula II where R^is the group r2s- using conventional methods known in the art as described earlier in this invention. - 16 43267 When acetophenones containing the group wherein R2 is as previously defined, are required as reactants for the preparation of starting compounds of Formula II, i.e., Wherein R2 and X are as previously defined, these acetophenones may be prepared by the following processes: (A) Friedel-Crafts Acylation of a known alkyl-, cycloalkyl-, aralkyl- or aryl phenyl sulfide with acetyl chloride or with acetic anhydride in the presence of AICI3 to yield the corresponding alkylthio-, cycloalky lthio-, aralkylthio or arylthioacetophenone which can be .converted to the corresponding sulfonyl derivatives by oxidation with hydrogen peroxide in acetic acid. These methods are described in the Journal of American Chemical Society 74, 547581, (1952) and U.S. 2,763,692.
(B) Coupling a diazotized aminoacetophenone with an aryl thiol or a substituted aryl thiol, said substituted thiol containing at least one substituent selected from the group consisting of halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro and cyano, to obtain the substituted arylthio acetophenone. Alternatively, a diazotized aryl amino compound, substituted with at least one of the above substituents can be coupled with a mercapto- 17 43267 acetophenone to obtain the substituted arylthioacetophenone. These procedures are described in Boll. sci. fac. chim. ind. Bologna 17, 33-43 (1959).
(C) Alkylation of an ο-, m- or p- mercaptoacetophenone with a known alkyl, eycloalkyl, aralkyl or substituted aralkyl halide, said substituted aralkyl halide substituted on the aryl moiety with at least one substituent selected from the group consisting of halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro and cyano to obtain the corresponding alkyl-, eycloalkyl-, aralkyl- or substituted aralkylthioacetophenone. This procedure is described in the Journal of American Chemical Society 78., 4792-7 (1956).
Oxidation of the products of processes (B) and (C) in the manner described in process (A) produced the corresponding Rjsulfonylacetophenones wherein Rj is as previously defined. - 18 43267 DESCRIPTION OF SPECIFIC EMBODIMENTS The following specific description is given to enable those skilled in the art to more clearly understand and practice the present invention. It should not be considered as a limitation upon the scope of the invention but merely as being illustrative and representative thereof. - 19 432»' PREPARATION A A mixture of 1.52 g. of 4-mercaptoacetophenone, 1.72 g. of 4-methoxybenzyl chloride and 1.5g. of anhydrous potassium carbonate in 50 ml. of acetone is stirred and refluxed under nitrogen. After 4 hours the solvent and excess 4-methoxybenzyl ' chloride are evaporated under vacuum and water is added to the residue. The resultant aqueous mixture is extracted with ether And.the ether extract washed with water, dried over magnesium sulfate and evaporated to dryness. The resulting residue is LO recrystallized from cyclohexane to yield 4-(4'-methoxybenzylthio)-acetophenone.
Similarly, replacing 4-methoxy benzyl chloride with other aralkyl halides or substituted aralkyl halides containing at least one substituent on the aryl moiety selected from the L5 group consisting of halo, lower alkyl, lower alkoxy, trifIuoromethyl, nitro and cyano is productive of the corresponding substituted aralkylthioacetophenones.
The starting compounds of Formula II are prepared from the above substituted aralkylthioacetophenones according to iO the procedure in U.S. 3,679,697.
. PREPARATION B A mixture of· 2 g. of 4-methylthioacetophenone, 5 g. of acetic acid, and approximately 3.8 g. of 30% hydrogen peroxide is heated.at 85° - 95°C. until an exothermic reaction is ini25 tiated, When the reaction subsides, .002 g. of palladium-oncarbon is introduced and the reaction mixture is filtered through diatomaceous earth. The filtrate is chilled to pre-, pipitate the product which is isolated by filtration and air dried to yield 4-methylsulfonyl acetophenone. - 20 43267 Similarly, replacing 4-methylthioacetophenone with other thioacetophenones, for example, 4-t-butylthioacetophenone, 4-benzylthioacetophenone, 4— (4'-chlorobenzylthio)acetophenone, 4-{4'-methoxybenzylthio)acetophenone, 4-phenylthioacetophenone, and 4-(4'-chlorophenylthio)acetophenone is productive of the following sulfonyl substituted aceto10 phenones: 4-t-butylsulfonylacetophenone, 4-benzylsulfonylacetophenone, 4-(4'-chlorobenzylsulfonyl)acetophenone, 4-(41-methoxybenzylsulfonyl)acetophenone, 4-phehylsulfonylacetophenone, and 4-(4'-chlorophenylsulfonyl)acetophenone.
The starting compounds of Formula II are prepared from the above sulfonyl substituted acetophenones according to the procedure in U.S. 3,679,697. - 21 43367 EXAMPLE 1.
A) A mixture of 1 g. of l-(2,4,/3-trichlorophenethyl) imidazole, 1.8 g. of 3,4-dichlorothiophenol and 1.5 g. of potassium carbonate in 50 ml. of acetone is stirred and refluxed for 4 hours. The solvent is evaporated under vacuum and 20 ml of water is added to the residue. The resultant aqueous mixture is extracted with ether and the ether extract washed with 50 ml. of a'saturated sodium chloride solution. The organic phase is dried over magnesium sulfate and evaporated to yield 1-[2,4-dichloro-β-(3',41-dichlorophenylthio)phenethyl] imidazole.
The oxalate salt of the free base is prepared by the dropwise addition of ethereal oxalic acid to the free base in ether until precipitation is complete. The product is collected by filtration and recrystallized from a mixture of acetone and ethyl acetate to yield l-[2,4-dichloroβ- (3 4 '-.-dichlorophenylthio) phenethyl ] imidazole oxalate, m.p. 161.5-163.5°C. - 22 43267 B) Similarly, substituting other starting materials of Formula XI for 1-(2,4,β-trichlorophenethyl)imidazole, for example, 1-.( β-chlorophenethyl) imidazole; 1-(p-chloro-4-ethylphenethyl)imidazole; 1-{(3-chloro-4-t-butylphenethyl)imidazole; 1-(p-ehloro-4-ethoxyphenethyl)imidazole; 1-(p-ehloro-4-n-butoxyphenethyl)imidazole; 1-(0-chloro-4-t-butoxyphenethyl)imidazole; 1—(4, fS-dichlorophenethyl)imidazole; 1- (3,4,p-trichlorophenethyl)imidazole; 1-(4-bromo-g-chlorophenethyl)imidazole; 1-(2,4-dibromo-g-chlorophenethyl)imidazole; 1-(B-chloro-4-fluorophenethyl)imidazole; 1-(p-chloro-2,4-difluorophenethyl)imidazole; 1- ((3-chloro-2-trifluoromethylphenethyl) imidazole; l-((S-chloro-4-trifluoromethylphenethyl)imidazole; 1-($-chloro-4-cyanophenethyl)imidazole, - 23 432θ7 1- (B-chloro-4-nitroph ene thyl) imidazole, and 1-(8-chloro-2-thiocyanatophenethyl)imidazole is productive of the following 1-((5-(31,4’-dichlorophenylthio)phenethyl]imidazoles which, where indicated, are further characterized as the acid addition salts by treatment in the conventional manner with the appropriate acid: 1- [ β- (31,41 -dichlorophenylthio) phenethyl] imidazole; 1-(4-ethyl-β-(31,4'-dichlorophenylthio)phenethyl]imidazole; 1-(4-t-butyl-β-(31,41-dichlorophenylthio)phenethyl]imidazole, nitrate salt, decomp. 142.5-146.5°C. 1-[4-ethoxy-β-(31,4'-dichlorophenylthio)phenethyl]im. idazole; 1-[4-n-butoxy-5~(31,41-dichlorophenylthio)phenethyl]imidazole; 1-(4-t-butoxy-g-(31,4’-dichlorophenylthio)phenethyl]imidazole; 1-[4-chloro-6-(31,4'-dichlorophenylthio)phenethyl]imidazole ; 1- (3,4-dichloro-B-(31,4'-dichlorophenylthio)phenethyl] imidazole, nitrate salt decomp. 133-137°C.; 1- [4-bromo-B“(3',41-dichlorophenylthio)phenethyl]im‘idazole; 1-(2,4-dibromo-β-(31,41-dichlorophenylthio)phenethyl] imidazole, nitrate salt decomp. 132.5-134.5°C.; 1-[4-fluoro-B-(3’,4'-dichlorophenylthio)phenethyl]imidazole; 1-(2,4-difluoro-β-(31> 4'-dichlorophenylthio)phenethyl] imidazole, oxalate salt, decomp. 172.5-175°C.; 1-(2-trifluoromethyl-3-(31,41-dichlorophenylthio)phenethyl] imidazole; - 24 43367 1-[4-trifluoromethyl~β-(3',4'-dichlorphenylthio)phenethyl] imidazole; 1-[4-cyano-β- (3', 4'-dichlorphenylthio)phenethyl]imidazole; 1-[4-nitro-β-(3',41-dichlorphenylthio)phenethyl]imidazole, and 1- [2-thiocyanato-g-(3',4’-dichlorophenylthio)phenethyl ]imidazole.
C) In like manner, substituting other starting materials of Formula III for 3,4-dichlorothiophenol, for example, 4-ohlorothiophenol and 2,4-dichlorothiophenol and using the above recited starting compounds of Formula II is productive of the following 1-[β-(R-thio)phenethyl]imidazoles which,where indicated, are further characterized as the acid addition salts by treatment in the conventional manner with the appropriate acid: 1-[β-(4'-chlorophenylthio)phenethyl]imidazole, oxalate salt, decomp, 147.5-149,°C.; 1-[8-(21,4'-dichlorophenylthio)phenethyl]imidazole; 1-[4-ethyl~3-(4'-chlorophenylthio)phenethyl]imidazole; 1-[4-ethyl~3-(2',4'-dichlorophenylthio)phenethyl)imidazole; 1-[4-t-butyl-3-(4'-chlorophenylthio)phenethyl]imidazole; 1-[4-t-butyl-B-(21,4'-dichlorophenylthio) phenethyl]imidazole; 1-[4-ethoxy-B-(41-chlorophenylthio)phenethyl]imidazole; 1-[4-ethoxy-R-(21,4'-dichlorophenylthio)phenethyl]imidazole - 25 1- [4-n-butoxy-g-(4'-chlorophenylthio)phenethyl]imidazole; 1-[4-n-butoxy-g-(21,4'-dichlorophenyIthio)phenethyl]imidazole; 1-[4-t-butoxy-g-(4'-chlorphenyIthio)phenethyl]imidazole 1-[4-t-butoxy-f}-(21,4'-dichlorophenylthio)phenethyl]imidazole; 1-[4-chloro-g-(4'-chlorophenylthio)phenethyl]imidazole, oxalate salt, decomp. 190-191°C.; 1- [4-chloro-g-(2',4 *-'dichlorophenyIthio]phenethyl]imidazole; 1-[2,4-dichloro-g~(4'-chlorophenylthio)phenethyl]im• idazole, nitrate salt,M.P. 169.5-170°C.; 1-[2,4-dichloro-g-(2', 4'-dichlorophenylthio)phenethyl] imidazole, nitrate salt, M.P. 150-151’C.; 1- [3,4-dichloro-g-(41-chlorophenylthio)phenethyl]im. idazole, nitrate salt, decomp. 123-125.5’C.; 1— [3,‘4-dichloro-g- (2' ,4 '-dichlorophenyIthio)phenethyljimidazole, oxalate salt, decomp. 169-171.5“C.; lr[4-bromo-g-(4'-chlorophenylthio)phenethyl]imidazole; 1-[4-bromo-g-(2',4'-dichlorophenylthio)phenethyljimidazole; 1-£ 2,4-dibromo-β-(4'-chlorophenylthio)phenethyl] imidazole; 1- [2,4-dibromo-fj-(2',4'-dichlorophenylthio)phenethyl]im idazole; .1-[4-£luoro-g-(4'-chlorophenylthio)phenethyl]imidazole; 1-[4-fluoro-p-(2',4'-dichlorophenylthio)phenethyl]imidazole; 1- [2,4-di£luoro-fS- (4'-chlorophenylthio)phenethyl]im.idazole; - 26 43267 1- [2,4-difluoro-β- (2', 4'-dichlorophenylthio)phenethyl]imidazole; 1-[2-trifluopomethy1-β- (4'-chlorophenylthio)phenethyl ]imidazole; 1-[2-tri£luoromethyl-g-(2',4'-dichlorophenylthio)phenethyl ]imidazole; 1-[4-trifluoromethyl-β-(4'-chlorophenylthio)phenethyl ] imidazole ; 1-[4-trifluoromethyl-g-(2',4'-dichlorophenylthio)phenethyl] imidazole; 1- [4-cyano-β-(4'-chlorophenylthio)phenethyl]imidazole; 1-[4-cyano-β-(2',4'-dichlorophenylthio)phenethyl]imidazole; 1-[4-nitro-β-(4'-chlorophenylthio)phenethyl]imidazole; and 1-[4-nitro-3~(2',4'-dichlorophenylthio)phenethyl]imidazole.
EXAMPLE 2 (A) A solution of 1 g. of 1-(2,4,β-trichlorophenethyl)imidazole in 10 ml. of tetrahydrofuran is added to a mixture of 1 g. of 2,4-dichlorobenylmercaptan and 220 mg. of 56% sodium hydride dispersion in 40 ml. of tetrahydrofuran.
After stirring for 12 hours at room temperature, the solvent is evaporated under vacuum and 10 ml. of water is added to the residue. The resultant aqueous mixture is extracted with ether and the ether extract washed with 50 ml. of a saturated sodium chloride solution. The organic phase is dried over magnesium sulfate and evaporated to yield 1[2,4-dichloro-B~(21,4'-dichlorobenzylthio)phenethyl]imidazole.
The nitrate salt of the free base is prepared by the dropwise addition of nitric acid to the free base in ether - 27 43267 until precipitation is complete. The product is collected by filtration and recrystallized from ethyl acetate to yield 1[2,4-dichloro-β-(2',4'-dichlorobenzylthio)phenethyl]imidazole nitrate, decomp. 133.5-134.5°C.
(B) Similarly, substituting other starting materials of Formula II, i.e., those recited in paragraph B of Example 1, is productive of the following 1-[β-(2*,4'-dichlorobenzylthio) phenethyl]imidazoles which, where indicated, are further characterized as the acid addition salts by treatment in the conventional manner with the appropriate acid: Ir[β-(2',4'-dichlorobenzylthio)phenethyl]imidazole; 1- I4-ethyl-g-(2', 4'-dichlorobenzylthio)phenethyl]imidazole; 1-[4-t-buty 1-(3-(2', 4'-dichlorobenzylthio)phenethyl)imidazole; 1- [4-ethoxy-(3- (21,4' -dichlorobenzylthio) phenethyl] imidazole; 1-[4-n-butoxy-B-(2',4'-dichlorobenzylthio)phenethyl]imidazole; 1-[4-t-butoxy-p-(2',4'-dichlorobenzylthio)phenethyl]imidazole; 1- [4-chloro-(3-(2',4'-dichlorobenzylthio)phenethyl]imidazole; 1-[3,4-dichloro-g-(2',4'-dichlorobenzylthio)phenethyl]im .idazole, nitrate salt, decomp. 107-110°C.; 1-[4-bromo~B-(2',4'-dichlorobenzylthio)phenethyl]imidazole; 1- [2,4-dibromo-£3 - (2', 4'-dichlorobenzylthio) phenethyl] imidazole; l-[4-fluoro-(3-(2',4'-dichlorobenzylthio)phenethylJimidazole; -2843267 1-[2,4-difluoro-0-(21,4’-dichlorobenzylthio)phenethyl] imidazole; 1-[2-trifluoromethy1-0-(2’,4'-diohlorobenzylthio)phenethyl] imidazole; l-[4-trifluoromethy1-0-(2',4'-dichlorobenzylthio)phenethyl] imidazole; 1-[4-cyano-0-(2',4'-dichlorobenzylthio)phenethyl]imidazole; 1-[4-nitro-0-(2',4'-dichlorobenzylthio)phenethyl]im10 . idazole; and •1- [2-thiocyanato-0-(2',4'-dichlorobenzylthio)phenethyl] imidazole.
(C) In like manner, substituting other starting materials of Formula III for 2,4-dichlorobenzylmercaptan, for example, 4-chlorobenzylmercaptan, 3,4-dichlorobenzylmercaptan or heptylmercaptan and using the starting materials of Formula II recited in paragraph B of Example 1 is productive of the following'1-[(3-(R-thio)phenethyl]imidazoles which, where indicated, are further characterized as the acid addition salts by treatment in the conventional manner with the appropriate acid: 1“[β-(4'-chlorobenzylthio)phenethyl]imidazole; 1—[β-(3',4’-dichlorobenzylthio)phenethyl]imidazole; 1- [β-(n-heptylthio)phenethyl]imidazole; 1-[4yethyl-B-(4'-chlorobenzylthio)phenethyl]imidazole; 1-[4-ethyl-3~(3',4'-dichlorobenzylthio)phenethy11 imidazole; 1-[4-ethyl-B~(n-heptylthio)phenethyl]imidazole; l-[4-t-butyl-B~(4'-chlorobenzylthio)phenethyl]imidazole; 1-oxalate salt; decomp. 156-158.5°C.; -2943267. 1-[4-t-butyl- β- (3', 4'-dichlorobenzylthio)phenethyl]imidazole; 1-[4-t-butyl-β-(n-heptylthio)phenethyl]imidazole; 1-[4-ethoxy-β-(4*-chlorobenzylthio)phenethyl]imidazole; .1-[4-ethoxy-β-(3’,41-dichlorobenzylthio)phenethyl]imidazole; 1-[4-ethoxy-β-(n-heptylthio)phenethyl] imidazole; 1- [4-n-butoxy-0-(41-chlorobenzylthio)phenethyl]imidazole, nitrate salt, decomp. 113-114°C.; 1-[4-n-butoxy-3~(31,41-dichlorobenzylthio)phenethyl]imidazole; 1-[4-n-butoxy-$-(n-heptylthio)phenethyl]imidazole, .oxalate salt, decomp. 124.5-130°C.; 1—[4-t-butoxy-β-(4’-chlorobenzylthio)phenethyl]imidazole; 1-[4-t-butoxy-β-(3',4'-dichlorobenzylthio)phenethyl]im•·idazole; 1-[4-t-butoxy-3-(n-heptylthio)phenethyl]imidazole; 1-[4-chloro-$-(4’-chlorobenzylthio)phenethyl]imidazole, oxalate salt, decomp. 148-149.5°C., nitrate salt, m.p . 103.5-105.5°C.; 1—[4-chloro-β-(3',4'-dichlorobenzylthio)phenethyl]imidazole; 1-[4-chloro-β-(n-heptylthio)phenethyl]imidazole; 1—[2,4-dichloro~3-(4'-chlorobenzylthio)phenethyl]imidazole, nitrate salt, M.P. 130.5-132eC.; 1- [2,4-dichloro·^-(3' ,4'-dichlorobenzylthio)phenethyl] imidazole, nitrate salt, decomp. 95-96.5°C.; 1-[2,4-dichloro~B-(n-heptylthio)phenethyl]imidazole, :’oxalate salt, M.P. 106-109°C.; 1- [3,4-dichloro-g-(4’-chlorobenzylthio)phenethyl]imidazole, oxalate salt, decomp. 174-175°C.; -3043267 1-[3,4-dichloro-β-(3',4'-dichlorobenzylthio)phenethyl]imidazole, oxalate salt, decomp. 176-177.5°C.; 1-[3,4-dichloro-β-(n-heptylthio)phenethyl]imidazole; 1-[4-bromo-g-(4'-chlorobenzylthio)phenethyl]imidazole; l-[4-bromo-6-(3',4'-dichlorobenzylthio)phenethyl]imidazole; 1-[4-bromo-8-(n-heptylthio)phenethyl]imidazole; 1- [2,4-dibromo~£>- (4 '-chlorobenzylthio) phenethyl] imidazole, nitrate salt, decomp. 126.5-128°C.; l-[2,4-dibromo-8-(3',4'-dichlorobenzylthio)phenethyl]imidazole ; 1-[2,4-dibromo-8-(n-heptylthio)phenethyl]imidazole; 1-[4-fluoro-β-(4'-chlorobenzylthio)phenethyl]imidazole; 1-[4-fluoro-β-(3',4'-dichlorobenzylthio)phenethyl]im15 idazole; 1-[4-fluoro-β-(n-heptylthio)phenethyl]imidazole; 1- [2,4-difluoro-B-(4'-chlorobenzylthio)phenethyl]imidazole; 1-[2,4-difluoro-β-(3',4’-dichlorobenzylthio)phen20 ethyl]imidazole, oxalate salt, decomp. 89.5-93,5°C.; 1-[2,4-difluoro-8-(n-heptylthio)phenethyl]imidazole; 1-[2-trifluoromethyl-B-(4'-chlorobenzylthio)phenethyl]imidazole; 1-[2-trifluoromethyl-β-(3',4’-dichlorobenzylthio)phen25 ethyl]imidazole, nitrate salt, decomp. 134.5-137°C.; 1-[2-trifluoromethyl-β-(n-heptylthio)phenethyl]imidazole; 1-[4-trifluoromethyl-B-(4'-chlorobenzylthio)phenethyl]imidazole; 1-[4-trifluoromethyl-β-(3',4'-dichlorobenzylthio)phen30 ethyl]imidazole; - 31 432θ7 1-[4-trifluoromethyl-β-(n-heptylthio)phenethyl]imidazole; 1-[4~cyano-8-(4'-chlorobenzylthio)phenethyl]imidazole; 1- [4-cyano-p-(3’,4'-dichlorobenzylthio)phenethyl]imidazole; 1-[4-cyano-fS-(n-heptylthio)phenethyl]imidazole; 1-[4-nitro-p-(4*-chlorobenzylthio)phenethyl]imidazole; 1- [4-nitro-8- (3 '.,4 ’-dichlorobenzylthio) phenethyl] imidazole; 1- [4-nitro-g-(n-heptylthio)phenethyl]imidazole; 1- (2-thiocyanato-B-(4’-chlorobenzylthio)phenethyl)imidazole; •1-(2-thiocyanato-g-(3',4’-dichlorobenzylthio)phenethyl] imidazole; and 1-[2—thiocyanato-β-(n-heptylthio)phenethyl]imidazole. EXAMPLE 3 Repeating the procedure recited in paragraph A of Example 1 using 1-(2,4,β-trichlorophenethyl)imidazole and 1-(3,4,3-trichlorophenethyl)imidazole as starting materials of Formula II and using 4-trifluoromethylthiophenol, 4-chloro.3-trifluoromethylthiophenol, 3,4,5-trichlorothiophenol and pentachlorothiophenol as starting materials of Formula III is productive of the following l-[3(R-thio)phenethyl]imidazoles which, where indicated, are further characterized as the acid addition salts by .treatment in the conventional manner with the appropriate acids - 32 432 1- [2,4-dichloro-β-(4'-trifluoromethyIphenylthio)phenethyl] imidazole, oxalate salt, decomp. 178-178.5°C.; 1-[2,4-dichloro-β-(4'-chloro-3'-trifluoromethyIphenylthio) phenethyl]imidazole, oxalate salt, decomp. 186-187.5°C.; l-[2,4-dichloro-8-(3' ,4',5'-trichlorophenylthio)phenethyl] imidazole, nitrate salt, decomp. 178-185.5°C.; 1- [2,4-dichloro-8-(pentachlorophenylthio)phenethyl]imidazole, nitrate salt, decomp. 201-202.5 °C.; 1- [3,4-dichloro-β-(4'-trifluoromethylphenylthio)phen10 ethyl]imidazole, oxalate salt, decomp. 170-171eC.; 1-[3,4-dichloro-B-(4'-chloro-3’-trifluoromethyIphenylthio) phenethyl]imidazole, oxalate salt, decomp. 165-166°C.; 1- [3,4-dichloro-8-(3',41,5'-trichlorophenylthio)phen15 ethyl]imidazole; and 1-[3,4-dichloro-8-(pentachlorophenylthio)phenethyl]imidazole. - 33 EXAMPLE 4 Repeating the procedure recited in paragraph A of Example 2 .but substituting other starting materials of Formula III for 2,4-d'ichlorobenzyl mercaptan, for example ethyl mercaptan, pentyl mercaptan, octyl mercaptan, nonyl mercaptan, dodecyl mercaptan octadecyl mercaptan, 3-phenylpropyl.mercaptan, cyclopentylpropyl mercaptan, cyclohexyl mercaptan, eyclohexylmethyl mercaptan, cyelohexylethyl mercaptan, eycloheptylmethyl mercaptan, allyl mercaptan, 2- octenyl mercaptan, 3- phenyl-2-propenyl mercaptan, 3- (4-chlorophenyl)-2-propenyl mercaptan 3- hexynyl mercaptan, 2-octynyl mercaptan, benzyl'mercaptan, 4- methylbenzy1 mercaptan, 4-t-btftylbenzyl mercaptan, 4-trifluoromethylbenzy1 mercaptan, 4-methoxybenzyl mercaptan, 3.4.5- trimethoxybcnzyl mercaptan, 4-n-butoxybenzyl mercaptan, 2.4.5- trichlorobenzyl mercaptan, - 34 4 32 67 4-bromobenzyl mercaptan, 4-fluorobenzyl mercaptan, 4-nitrobenzyl mercaptan, and 4-cyanobenzyl mercaptan, is productive of the following 1-[2,4-dichloro-(3-(R-thio)phenethyl3imidazoles which, where indicated, are further characterized as the acid addition salts by treatment in the conventional manner with the appropriate acid: 1-[2,4-dichloro-β-(ethylthio)phenethyl]imidazole; 1-[2,4-dichloro-β-(n-pentylthio)phenethyl]imidazole, oxalate salt, coalesces 99°C.; 1- [2,4-dichloro-β-(n-octylthio)phenethyl]imidazole, oxalate salt, M.P. 101.5-103.5°C.; 1- [2,4-dichloro-β-(n-nonylthio)phenethyl]imidazole, oxalate salt, gels 82.5°C.; 1- [2,4-dichloro-β-(n-dodecylthio)phenethyl]imidazole, oxalate salt, M.P. 124.5°C.; 1-[2,4-dichloro-β-(octadecylthio)phenethyl]imidazole, oxalate salt, gels 91.5-150°C.; 1-[2,4-dichloro-β-(3-phenylpropylthio)phenethyl]imidazole, oxalate salt, M.P. 87.5-90°C.; 1- [2,4-dichloro-g-(cyclopentylpropylthio)phenethyl]imidazole; 1-[2,4-dichloro-β-(cyclohexylthio)phenethyl]imidazole nitrate salt, M.P. 114.5-117.5°C.; l-[2, 4-dichloro~8-(cyclohexylmethylthio)phenethyl]im. idazole, oxalate salt, decomp. 122.5-140°C.; 1- [2,4-dichloro^- (cyclohexylethylthio)phenethyl] imidazole, oxalate salt, decomp. 104-108.5°C; 1-[2,4-dichloro-β-(cycloheptylmethylthio)phenethyl]imidazole; - 35 . 43267 1- [2,4- diehloro- g- (ally Ithio) phene thyl] imidazole oxalate s^lt, M.P. 84.5-123’C.; 1-(2,4-dichloro-g-(2-octenyIthio)phenethyl]imidazole, oxalate salt, M.P. 112.5-116.5°C.; 1- [2,4-dichloro-8-(3-pheny1-2-propenyIthio)phenethyl]im idazole, oxalate salt, decomp. 151-160.5°C.; 1-[2,4-dichloro- g-(4’-chlorophenyl)-2-propenyIthio)phenethyl]imidazole, nitrate salt, decomp. 123-126°C. 1-(2,4-dichloro-8-(3-hexynyIthio)phenethyl]imidazole, oxalate salt, M.P. 90.5-95eC.; -- 1-(2,4-dichloro-8-{2-octynyIthio)phenethyl]imidazole, oxalate salt, decomp. 118-119.5°C.; 1-(2,4-dichloro-8-(benzyIthio)phenethyl]imidazole; . nitrate salt, m.p. 110-112°C.; 1-(2,4-dichloro-8-(4'-methylbenzylthio)phenethyl]imidazole, nitrate salt, M.P. 110.5-112°C.; 1- [2,4-dichloro-8-(4*-t-butylbenzylthio)phenethyl]imidazole, nitrate salt, decomp. 162.5-163°C.; 1-[2,4-dichloro-8-(4'-trifluoromethylbenzyIthio)phenethyl] imidazole, nitrate salt, decomp. 112-114°Ο.; 1-(2,4-dichloro-8-(4'-methoxybenzylthio)phenethyl]imidazole, nitrate salt, decorap. 118-119.5°C.; 1-[2,4-dichloro-8-(3*,4',5’-trimethoxybenzylthio)phenethyl] imidazole, oxalate salt, gels 147°C.; 1-£2,4-dichloro-8-(4'-n-butoxybenzylthio)phenethyl]imidazole; 1- [2,4-dichloro-8-(2',4',5'-trichlorobenzyIthio)phenethyl] imidazole, nitrate salt, decomp. 172.5-173.5°C. 1-(2,4-dichloro-8-(4'-bromobenzyIthio)phenethyl]imidazole, nitrate salt, decomp. 137-138°C.; 1-(2,4-dichloro-8- (4'-fluorobenzyIthio)phenethy1]imidazole, nitrate salt, decomp. 104.5-107.5°C.; - 36 4 3267 1-(2,4-dichloro- β- (4'-nitrobenzylthio)phenethyl]imidazole, nitrate salt, decomp. 129.5-132°C.; 1-[2,4-dichloro-β-(41-cyanobenzylthio)phenethyl]imidazole, nitrate salt, decomp. 119.5-123°C.; EXAMPLE 5 Repeating the procedure recited in paragraph A of Example 1 using 1-(4,β-dichlorophenylethyl)imidazole and 1-[2,4,β-trichlorophenethyl)imidazole as starting materials of Formula II and using other starting materials of Formula III for 3,4-dichlorothiophenol for example, thiophenol, β-thionaphthol, 4-methylthiophenol, 4-methoxythiophenol, 3-methoxythiophenol, 2- chlorothiophenol, 3- chlorothiophenol, 2,5-dichlorothi ophenol, 4- bromothiophenol, . 4-fluorothiophenol, 4-nitrothiophenol, 4-aminothiophenol, 4-acetamidothiophenol, and 4-cyanothiophenol, is productive of the following 1-[4-chloro-g-(R-thio)phenethyl]imidazoles and 1-[2,4-dichloro-B-(R-thio)phenethyl]imidazoles which, where indicated, are further characterized as the acid addition salts by treatment in the conventional manner with the appropriate acid: 1- [4-chloro-B-(phenylthio)phenethyl]imidazole, oxalate salt, decomp. 166-167°C.; - 37 43267 1-[4-chloro-β-(2-naphthylthio)phenethyl]imidazole, oxalate salt, M.P. 193.5-194’C.; 1- [4-chloro-β-(4'-methylphenylthio)phenethyl]imidazole, oxalate salt, decomp. 199.5-200°C.; 1-[4-chloro-β-(41-methoxyphenylthio)phenethyl]imidazole, oxalate salt, decomp. 177-l78eC.; 1-[4-chloro-β-(3*-methoxyphenylthio)phenethyl]imidazole, oxalate salt, M.P. 164.5-165.5°C.; 1- [4-chloro~B-(2'-chlorophenylthio)phenethyl)imidazole, oxalate salt, M.P. 177-178ttC.; 1*[4-phloro-$-(3'-chlorophenylthio)phenethyl]imidazole, oxalate salt, M.P. 169.5-171.5°C.? 1-[4-chloro-6-(2',5'-dichlorophenylthio)phenethyl]imdazole, oxalate salt, M.P. 181.5-183.5°C.? 1- [4-chloro-g-(4'-bromophenylthio)phenethyl]imidazole, oxalate salt, decomp. 185-186.5°C.; 1-[4-chloro-$-(4'-fluorophenylthio)phenethyl]imidazole, oxalate salt, M.P. 182.5-183°C.; 1- [4-chloro-8-(4'-nitrophenylthio)phenethyl]imidazole, oxalate salt, M.P. 203-204.5°C. ,· 1- [4-chloro-8~(4'-aminophenylthio)phenethyl]imidazole? 1- [4-chloro'-g- (4'-acetamidophenylthio)phenethyl] imidazole, oxalate salt, M.P. 149.5-152°C.; 1-[4-chloro-8-(4'-cyanophenylthio)phenethyl)imidazole; 1-[2,4-dichloro-$-(phenylthio)phenethyl]imidazole; 1-[2,4-dichloro-o~(2-naphthylthio)phenethyl]imidazole; 1- [2,4-dichloro-8 - (41-methylphenylthio)phenethyl]imidazole; 1- [.2,4-dichloro-g - (4' -methoxyphenylthio) phenethyl ] imidazole; - 38 4 3267 1-[2,4-dichloro-β-(3'-methoxyphenyIthio)phenethyl]imidazole; 1-[2,4-dichloro-3-(2'-chlorophenylthio)phenethyl]imidazole; 1-[2,4-dichloro-3-(3'-chlorophenylthio)phenethyl]imidazole; 1- [2,4-dichloro-3-(21,51-dichlorophenylthio)phenethyl]imidazole; 1-[2,4-dichloro-3-(4'-bromophenylthio)phenethylJim10 idazole; 1-(2,4-dichloro-3-(4'-fluorophenylthio)phenethyl]imidazole; 1-[2,4-dichloro-3-(41-nitrophenylthio)phenethyl]imidazole; 1-[2,4-dichloro-3-(4’-aminophenylthio)phenethyl]imidazole; 1-[2,4-dichloro-3~(4'-acetamidophenylthio)phenethyl]imidazole; and 1-[2,4-dichloro-β— (4'-cyanophenyIthio)phenethyl]im20 idazole. - 39 EXAMPLE 6 To a solution of 400 mg. of l-[4-chloro-/3-(4'-aminophenylthio)phenethyl]imidazole oxalate in 20 ml. of tetrahy' drofuran containing 1 ml. of triethylamine is added 0.5 ml. of hexanoyl chloride. After stirring for 30 minutes at room temperature, the solvent is evaporated under vacuum and aqueous potassium carbonate is added to the residue. The resultant aqueous mixture is extracted with dichloromethane and the organic phase is acidified with oxalic acid. The product which precipitates .is filtered off and recrystallized from a mixture of acetone and ethyl acetate to yield l-[4-chloroβ-(4'-hexanoylaminophenylthio)phenethyl]imidazole oxalate, M.P. 98.5-102°C.„ Similarly, substituting other, acid chlorides for 'hexanoyl chloride, for example propionyl chloride, n-valeryl chloride, decanoyl chloride and .the like is productive of the corresponding 1-[4-chloro-β-(4'-propionylaminophenylthio)phenethyl]imidazole oxalate; 1-[4-chloro-B-(4'-valeroylaminophenylthio)phenethyl]imidazole oxalate; 1-[4-chloro~B-[4'-decanoylaminophenylthio)phenethyl]imidazole oxalate, and so forth. - 40 43267 EXAMPLE 7 j- [4-chloro-/3- (4'-chlorophenylthio)phenethyl] imidazole, nitrate ( l’g.) is treated with aqueous potassium carbonate until a pH of approximately 11 is obtained, whereupon the free base, i.e., l-[4-chloro-0-(4'-chlorophenylthio)phenethyl] imidazole, which separates is extracted with dichloromethane. The extract is dried with magnesium sulfate and evaporated.
To the resulting residue, in 50 ml. of chloroform at 0°c. is slowly added with stirring, a solution of 700 mg. of 85% . m-chloroperbenzoic acid in 50 ml. of chloroform. When the addition is complete, stirring at 0°C. is continued for approximately 3 hours. Thereafter, the reaction mixture is washed with aqueous potassium carbonate and aqueous sodium chloride, dried over magnesium sulfate and evaporated. The residue is crystallized from benzene to yield l-[4-chloro-/3(4'-chlorophenylsulfinyl)phenethyl!imidazole, M.P. 139-140°C., which is further characterized as the oxaiaue salt, M.P. 167-167.5°C, Similarly, repeating the above procedure on the 1-[β— (R-thio)phenethyl]imidazole salts obtained in Examples 1 thru is productive of the corresponding 1-[β-(R-sulfinyl)phenethyl) imidazoles which can be further characterized by conversion in the usual manner to the indicated acid addition salts, e.g., 1-[2,4-dichloro~B-(n-dodecylsulfinyl)phenethyl]imidazole, oxalate salt, decomp. 134-138°C.; 1-[4-chloro-8-(4'-chlorobenzylsulfinyl)phenethyl]imidazole, nitrate salt, decomp. 161.5-162°C.; and so •forth. - 41 '•r.-r· 2.6 7 EXAMPLE 8 1-[4-(chloro-β-(4'-chlorophenylthio)phenethyl]imidazole nitrate (1 g.) is treated with aqueous potassium carbonate until a pH of approximately 11 is obtained whereupon the free base, i.e. 1-[4-chloro-0-(4'-chlorophenylthio) phenethyl]imidazole, which separates is extracted with dichloromethane. The extract is dried with magnesium sulfate and. evaporated. To the resulting residue in 50 ml. of chloroform at room temperature is slowly added with stirring a solution of 1.7 g. of 85S m-chloroperbenzoic acid in 50 ml. of chloroform. When the addition is complete stirring at room temperature is continued for approximately 24 hours. Thereafter, the reaction mixture is washed with aqueous potassium carbonate and aqueous sodium chloride, dried over magnesium sulfate and evaporated. The residue is crystallized from benzene to yield 1-t4-chloro~0-[4'chlorophenylsulfonyl)phenethyl]imidazole, M.P. 176-178.5°C.
Similarly, repeating the above procedure on the 1—[β— (R-thio)phenethyl]imidazoles or acid addition salts obtained in Examples 1 thru 6 is productive of the corresponding 1[β-R-sulfonyl)-phenethyl]imidazoles which can be further characterized by conversion in the usual manner to the indicated acid addition, salts, e,g., 1- [2,4-dichloro-0-(dodecylsulfonyl)phenethyl]imidazole, oxalate salt, decomp. 105.5-110°C.; 1- [4-chloro~8-(4'-chlorobenzylsulfonyl)phenethyl]imidazole, nitrate salt, decomp. 181°C.; and so forth - 42 43267 EXAMPLE 9 A solution of 85% m-chloroperbenzoic acid in chloroform (2 g/100 ml.) is added dropwise, over a period of one hour, to a stirred solution of 2.53 g. of 1-[|3-chloro-4-methylthio5 phenethyl]imidazole in 150 ml. of chloroform at 0°C.. After hours, the resultant solution is washed with aqueous potassium carbonate and with water. The organic phase is separated and dried over magnesium sulfate. Evaporation of the solvent yields 1-[p-chloro-4-methylsulfinylphenethyl]imidazole.
Similarly, replacing l-[P-chloro-4-methylthiophenethyl] imidazole with other l-[p-chloro~thiophenethyl]imidazoles, for example, 1-[p-chloro-4-t-butylthiophenethyl]imidazole; 1-[0-chloro-4-benzylthiophenethyl]imidazole; l-lP-chloro-4-(4‘-chlorobenzylthio)phenethyl]imidazole; l-[0-chloro-4~(4'-methoxybenzylthio)phenethyl]imidazole; - 43 43267 I-[p-chloro-4-phcnylthiophenethyl]imidazole, and 1-[p-chloro-4-(4'-chlorophenylthio)phenethyl]imidazole, is productive of: 1-[p-chloro-4-t-butylsulfinylphenethyl]imidazole; - 1-[p-chloro-4-benzylsulfinylphenethyl]Imidazole; 1-[p-chloro-4-(4*-chlorobenzylsulfinyl)phenethyl]imidazole; 1-[p-chloro-4-(4 *-methoxybenzylsulfinyl)phenethyl]imidazole; 1-[p-chloro-4-phenylsulfinylphenethyl]imidazole, and 0 1-[p-chloro-4-(41-chlorophenylsulfinyl)phenethyl]imidazole.
EXAMPLE 10 Repeating the procedure recited in paragraph A of Example 1 using 3,4-dichlorothiophenol as the starting material of Formula III and using other starting materials of Formula II for 1-(2,4,p-trichlorophenethyl)imidazole, for example, 1— (p-chloro-4-methylthiophenethyl)imidazole; 1-(p-chloro-4-t-butylthiophenethyl)imidazole; 1-(p-chloro-4-benzylthiophenethyl)imidazole; 1-[p-chloro-4-(4'-chlorobenzylthio)phenethyl]imidazole; 1-[p-chloro-4-(4’-methoxybenzylthio)phenethyl]imidazole; 1-(p-chloro-4-phenylthiophenethyl)imidazole; 1- [p-chloro-4-(4'-chlorophenylthio)phenethyl]imidazole; 1- (P-chloro-4-methylsulfinylphenethyl)imidazole; 1- (p-chlqro-4-t-butylsulfinylphenethyl) imidazole; 1- (p-chloro-4-benzylsulfinylphenethyl)imidazole; 1- [p-chloro-4-(4’-chlorobenzylsulfinyl)phenethyl]imidazole; 1-lP-chloro-4-(41-methoxybenzylsulfinyl)phenethyl]imidazole; 1-(P-chloro-4-phenylsulfinylphenethyl)imidazole; r 1- [p-chloro-4-(4 *-chlorophenylsulf inyl)phenethyl]imidazole; - 44 43267 1-^-chloro-4-methylsulfonylphenethyl)imidazole; 1-((5-chloro-4-t-butylsulfonylphenethyl)imidazole; 1-(f5-chloro-4-benzylsulfonylphenethyl)imidazole; 1-[g-chloro-4-(4'-chlorobenzylsulfonyl)phenethyl]imidazole; 1- [ β-chloro-4-{4'-methoxybenzylsulfonyl)phenethyl]imidazole; 1-18-chloro-4-phenylsulfonylphenethyl)imidazole, and 1-[3-chloro-4-(41-chlorophenylsulfonyl)phenethyl]imidazole; is productive of the following 1-[β-(3',4'-dichlorophenylthio)phenethyl]imidazoles: 1-(4-methylthio-0-(3',4'-dichlorophenylthio)phenethyl]imidazole; 1- [4-t-butylthio^- (3', 4'-dichlorophenylthio) phenethyl J imidazole; 1-[4-benzylthio-0-(3',4'-dichlorophenylthio)phenethyl]imidazole;· 1- [4-(4-chlorobenzyIthio)-β~(3*,4'-dichlorophenylthio)phenethyl ] imidazole; 1-[4-(4-methoxybenzyIthio)-β-(3',4'-dichlorophenylthio) phenethyl] imidazole; 1-[4-phenylthio-g-(3',4'-dichlorophenylthio)phenethyl]imidazole; 1- [4-(4-chlorophenylthio)-β-(3',4'-dichlorophenylthio)phenethyl ]imidazole; 1-[4-methylsulfinyl-β-(3',4'-dichlorophenylthio)phenethyl ]imidazole; 1-14-t-bu'tylsulf inyl-β - (31,41 -dichlorophenylthio) phenethyl] imidazole; - 45 43267 l-[4-benzylsulfinyl-β-(31,4'-dichlorophenylthio)phenethyl] imidazole ; 1-14-(4-chlorobenzylsulfinyl)-β-(31,4’-dichloropheny1thio)phenethyl]imidazole; 1-[4-(4-methoxybenzylsulfiny1)-β-(31,4 *-dichlorophenylthio) phenethyl ] imidazole; 1-[4-phenylsulfinyl-β-(31,41-dichlorophenylthio)phenethyl ] imidazole ; 1-f4-(4-chlorophenylsulfinyl)-β-(3',4'-dichlorophenylthio) phenethyl]imidazole; 1- [4-methylsulfonyl-β-(3',4 *-dichlorophenylthio)phenethyl] imidazole; 1-[4-t-butylsulfonyl-3~(3 *,4'-dichlorophenylthio)phenethyl ] imidazole; 1-t4-benzylsulfonyl-β-(3',4'-dichlorophenylthio)phenethyl] imidazole ; 1-[4-(4-chlorobenzylsulfonyl)-β-(3',41-dichlorophenylthio) phenethyl] imidazole; 1-[4-(4-methoxybenzylsulfonyl)-β-(3',41-dichloropheny lthio) phenethyl]imidazole; 1-[4-phenylsulfonyl-B-(3’,4’-dichlorophenylthio)phenethyl] imidazole; and 1- [4-(4-chlorophenylsulfonyl)-β-(3',4'-dichlorophenylthio) phenethyl]imidazole.
EXAMPLE 11 Repeating the procedure recited in paragraph A of Example 2 using 4-chlorobenzyl mercaptan as the starting material of Formula III and using other starting materials of Formula II for 1-(2,4,β-trichlorophenethyl)imidazole, i.e., those starting materials of Formula II recited in Example 10, - 45 43267 is productive of the following 1-[β-(4'-chlorobcnzylthio)phenethyl ]imidazoles: 1-[4-methylthio-β-(4'-chlorobenzylthio)phenethyl]imidazole; 1-[4-t-butylthio-β-(41-chlorobenzylthio)phenethyl]imidazole; 1- [4-benzylthio-β-(41-chlorobenzylthio)phenethyl]imidazole; 1- [4-(4-chlorobenzylthio)-β-(4'-chlorobenzylthio)phen10 ethyl]imidazole; 1-[4-{4-methoxybenzylthio)-β-(4'-chlorobenzylthio)phenethyl ]imidazole; 1- [4-phenylthio-β-(4'-chlorobenzylthio)phenethyl]imidazole; 1-[4-(4-chlorophenylthio)-β-(4'-chlorobenzylthio)phenethyl ]imidazole; 1-[4-methylsulfinyl-B-(4'-chlorobenzylthio)phenethyl]imidazole; 1-[4-t-butylsulfinyl-β-(4'-chlorobenzylthio)phenethyl]im20 idazole; 1-[4-benzylsulfinyl-β-[4'-chlorobenzylthio)phenethyl]imidazole; 1- [4-(4-chloroben2ylsulfinyl)-β-(4'-chlorobenzylthio)phen ethyl]imidazole; 1-[4-(4-methoxybenzylsulfinyl)-β-(4'-chlorobenzylthio) phenethyl] imidazole; 1[4-phenylsul( inyl-β-(4'-chlorobenzylthio)phenethyl]imidazole; 1- [4- (4-chlorophenylsulfinyl)-S- (4 '-chl.orobenzyl30 thio)phenethyl]imidazole; - 47 43267 1-[4-methylsulfonyl-(3-(4’-chlorobenzylthio)phenethyl] imidazole; 1-[4-t-butylsulfonyl-g-(41-chlorobenzylthio)phenethyl] imidazole ; 1-[i-benzylsulfonyl-g-(4'-chlorobenzylthio)phenethyl]imidazole; 1“(4-(4-chlorobenzylsulfonyl)-β-(4'-chlorobenzylthio) phenethyl ]imidazole; 1-[4-(4-methoxybenzylsulfonyl)-β-(4 ’-chlorobenzylthio) phenethyl]imidazole; 1“[4-phenylsulfonyl··^-(4'-chlorobenzylthio)phenethyl]imidazole; and . 1-[4-(4-chlorophenylsulfonyl)-β-(4'-chlorobenzyl- . thio)phenethyl]imidazole. - 48 43267 EXAMPLE 12 Repeating the procedure recited in Example 7 (using the appropriate quantity of m-chloroperbenzoic acid) on the products obtained in Examples 10 and 11 is productive of the following 1-[β-R-sulfinyl)phenethyl]imidazoles; 1-[4-phenylthio-g- (3',4'-dichlorophenylsulfinyl)phenethyl] imidazole; 1-[4-(4-chlorophenylthio)- g- (3',4'-dichlorophenylsulf inyl) phenethyl]imidazole;. 1-[4-methylsulfinyl-g-(3',4'-dichlorophenylsulfinyl)phenethyl ] imidazole ; 1- [4-t-butylsulfinyl-B-(3',4'-dichlorophenylsulfinyl)phenethyl]imidazole; 1-[4-benzylsulfinyl-B-(3',4'-dichlorophenylsulfinyl)phenethyl]imidazole; 1-[4-(4-chlorobenzylsulfinyl)-β-(3',4'-dichlorophenyl’ sulfinyl)phenethyl]imidazole; 1- [4- (4-methoxybenzylsulfinyl)-B-(3',4'-dichlorophenylsulf inyl) phenethyl]imidazole; 1- [4-phenylsulfinyl-B-(3',4'-dichlorophenylsulfinyl)phenethyl] imidazole; 1-[4-(4-chlorophenylsulfinyl)-B-(3',4'-dichlorophenylsulf inyl) phenethyl] imidazole; 1-[4-methylsulfonyl-β-(3',4'-dichlorophenylsulfinyl)phenethyl] imidazole; 1-[4-t-butylsulfonyl-β-(3',4'-dichlorophenylsulfiny1) phenethyl) imidazole; l-[4-benzylsulfonyl-B-(3',4’-dichlorophenylsulfinyl)phenethyl] imidazole; 1- [4- (4-chlorobenzylsulfonyl)-B-(3',4'“dichlorophenylsulfinyl) phenethyl] imidazole; - 49 43267 1-[4-(4-methoxybenzylsulfonyl)-β-(3',4'-dichlorophenyls ulfinyl)phene thyl]imidazole; 1-[4-phenylsulfonyl-B-(3',41-dichlorophenylsulfinyl)phenethyl] imidazole; 1- [4-(4-chlorophenylsulfonyl-β-(3*,4' -dichlorophenylsulfinyl) phenethyl]imidazole; 1- [4-phenylthio-β- (4.'-chlorobenzylsulfinyl) phenethyl] imidazole ; 1- [4- (4-chlorophenylthio)^- (4 ’-chlorobenzy lsulf inyl) phen ethyl]imidazole; 1-[4-methylsulfinyl-β-(4'-chlorobenzylsulfinyl)phenethyl ] imidazole ; 1-[4-t-butylsulfinyl-β-(4*-chlorobenzylsulfinyl)phenethyl] imidazo-le; 1-[4-benzylsulfinyl-β-(41-chlorobenzylsulfinyl)phenethyl ]imidazole; 1- [4-(4-chlorobenzylsulfinyl)-B-(4'-chlorobenzylsuJLfinyl) phenethyl] imidazole; 1- [4- (4-methoxybenzylsulfinyl)-β-(4'-chlorobenzylsulf inyl) phenethyl] imidazole; 1-[4-phenylsulfinyl~3-(4'-chlorobenzylsulfinyl)phenethyl] imidazole; 1-[4-(4-chlorophenylsulfinyl)-β-(4'-chlorobenzy1sulfinyl)phenethyl]imidazole; 1-[4-methylsulfonyl·^-(4'-chlorobenzylsulfinyl)phenethyl] imidazole; 1-[4-t-butylsulfonyl-β-(41-chlorobenzylsulfinyl)phenethyl] imidazole; 1-[4-benzylsulfonyl-β-(4’-chlorobenzylsulfinyl)phenethyl] imidazole; - 50 4326 1-[4-(4-chlorobenzylsulfonyl)- β- (4'-chlorobenzylsiilfinyl) phenethyl] imidazole; and l-[4-(4-methoxybenzylsulfonyl)-β-(4'-chlorobenzylsulfinyl) phenethyl] imidazole.
EXAMPLE 13 Repeating the procedure recited in Example 8 on the products obtained in Examples 10 and 11 is productive of the following 1-[β-(R-sulfonyl)phenethyl]imidazoles: 1- [4-phenylthio-β-(3’,4'-dichlorophenylsulfonyl)phen10 ι ethyl]imidazole; 1-[4-(4-chlorophenylthio)-β-(3',4'-dichloropheny1sulfonyl)phenethyl]imidazole; l-[4-phenylsulfinyl-β-(3',4'-dichlorophenylsulfonyl)phen ethyl]imidazole; 1-[4-(4-chlorophenylsulfinyl)-β-(3',4'-dichlorophenylsulfonyl) phenethyl]imidazole; 1-[4-methylsulfonyl-5-(3',4'-dichlorophenylsulfonyl)phen ethyl]imidazole; 1-[4-t-butylsulfonyl-3-(31,4'-di chlorophenylsulfonyl)20 phenethyl]imidazole; 1-[4-benzylsulfonyl-B-{3',4'-dichlorophenylsulfonyl)phenethyl]imidazole; 1-[4-(4-chlorobenzylsulfonyl)-β- (3',4'-dichlorophenylsulfonyl) phenethyl] imidazole; 1- [4-(4-methoxybenzylsulfonyl)-β-(3',4'-dichlorophenylsulfonyl) phenethyl] imidazole; - 51 43367 1- [4-phenylsulfonyl-β-{31,4'-dichlorophenylsulfonyl)phenethyl] imidazole; 1-(4-(4-chlorophenylsulfonyl)-β-(3',41-dichlorophenyl-, sulfonyl)phenethyl]imidazole; 1-(4-phenylthio-β-(4'-chlorobenzylsulfonyl)phenethyl]imidazole; ' 1- [4-(4-chlorophenylthio)-β-(41-chlorobenzylsulfonyl)phen ethy1]imidazole; 1-[4-phenylsulfinyl-β-(41-chlorobenzylsulfonyl)phenethyl] imidazole; 1-(4-(4-chlorophenylsulfinyl)-β-(41-chlorobenzylsulfonyl) phenethyl]imidazole; - 1-[4-methylsulfonyl-β-(4'-chlorobenzylsulfonyl)phenethyl]imidazole; 1-[4-t-butylsulfonyl-3-(4'-chlorobenzulsulfonyl)phenethyl] imidazole; 1-[4-benzylsulfonyl-B-(4'-chlorobenzylsulfonyl)phenethyl] imidazole; 1-[4-(4-chlorobenzylsulfonyl)-β-(4'-chlorobenzylsulfonyl) phenethyl] imidazole; 1-[4-(4-methoxybenzylsulfonyl)-β-(4'-chlorobenzylsulfonyl) phenethyl] imidazole; 1-[4-phenylsUlfonyl-B-(4'-chlorobenzylsulfonyl)phenethyl] imidazole; and 1- [4-(4-chlorophenylsulfonyl)-β-(4'-chlorobenzylsulfonyl) phenethyl]imidazole.
EXAMPLE 14 Repeating the procedure recited in Example 1, using reactants as dictated by the particular 1-[β-(R-thio)phenethyl] imidazole desired, is productive of the following compounds which, where indicated, are further characterized as the acid addition salts by treatment in the conventional manner with the appropriate acid. 1-[2,4-dichloro-β-(4'-nitro-3'-trifluoromethylphenyIf thio)phenethyl]imidazole, nitrate salt, decomp. 127.5-130.5°C.; 1-[4-trifluoromethyl-6-(4'-tert-butylphenylthio)phenethyl] imidazole, oxalate salt, M.P. 161-162°C.; 1-[2,4-dimethyl-g-(3',4'-dichlorophenylthio)phenethyl]imidazole, nitrate salt, decomp. 165.5-166°C.; 1-[4-methoxy-β-(3', 4'-dichlorophenylthio)phenethyl] imidazole, oxalate salt, M.P. 145.5°C.; 1- [4-methoxy-β-(4'-tert-butylphenylthio)phenethyl] imidazole, oxalate salt, M.P. 139.5-141.5°C.; 1- [2,4-dimethoxy-0-(3',4'-dichlorophenylthio)phenethyl] imidazole, nitrate salt, decomp. 155.5-158°C.t 1-[4-nitro-β-(pentachlorophenylthio)phenethyl]imidazole, nitrate salt, decomp. 163.5-165.5°C; .1-[2,4-dichloro-β-(n-butoxyphenylthio)phenethyl]imidazole, oxalate salt, m.p. 143-144°C.; 1- [4-cyano-0-(pentachlorophenylthio)phenethyl]imidazole, nitrate salt, m.p. 182.5-183.5°C. (foaming); 1-[4-n-butylthio-B-(4'-chlorophenylthio)phenethyl]imidazole; and 1- [4-methylthio~8-(3',41-dichlorophenylthio)phenethyl] imidazole. - 53 43267 EXAMPLE 15 Repeating the procedure recited in Example 2, using reactants as dictated by the particular l-[g-(R-thio)phenethyl] imidazole desired, is productive of the following compounds which, where indicated, are further characterized as the acid addition salts by treatment in the conventional manner with the appropriate acid: 1- [2,4-dif luoro- 8- (n-nonylthio)phenethyl]imidazole, oxalate salt, M.P. 79.5-84’C.; 1-[2.,4-dimethyl-8-(4'-chlorobenzylthio)phenethyl]imidazole, oxalate salt, decomp. 80.5-83°C.; 1-[4-methqxy-8-(3-phenylpropyIthio)phenethyl]imidazole, oxalate salt, M.P. 75-83’C; 1- [4-methoxy-8-(n-dodecylthio)phenethyljimidazole; oxalate salt, m.p, 90-93°C.; 1- [2,4-dichloro-8-(l'-naphthyImethylthio)phenethyl]imidazole, oxalate salt, coalesces 86°C.., foams 86-121.5°C.; 1-[4-chloro-8-(ethyIthio)phenethyl]imidazole, oxalate salt, M.P. 157-158°C.; 1-[2,4-dichloro-8-(n-undec-10-enylthio)phenethyl]imidazole, oxalate salt, M.P. 82-107°C.; 1-[2,4-dichloro-8-(3-(4'-methylphenyl)prop-2-enylthio)phenethyl]imidazole, nitrate salt, m.p. 133.5-137°C.; 1- [-2,4-dichloro-8- (3- (41 -tert-butylphenyl)prop-2-enylthio)phenethyl]imidazole, nitrate salt, m.p. 147-153.5° 1-[2,4-dichloro-8-(4-phenylbut-3-enyIthio)phenethyl ]imidazole; 1-[2,4-dichloro-8-(3-(4'-chlorophenyl)propylthio)phenethyl] imidazole, oxalate salt, m.p. 111-113’C.; 1- [2,4-dichlorO~8-(prop-2-ynyIthio)phenethyl]imidazole; - 54 43267 1-[4-methyIthio-β-(3',4'-dichlorobenzylthio)phenethyl] imidazole; 1-[4-n-butyl thio-g-(4'-chlorobenzyitmo) phenethyl] imidazole ; 1-[2,4-dichloro-β-(n-hexyIthio)phenethyl]imidazole; 1-[2,4-dibromo-β-(n-hexyIthio)phenethyl]imidazole? 1-[2,4-dibromo-β-(n-octyIthio)phenethyl]imidazole; 1-[2,4-difluoro-β-(n-octyIthio)phenethyl]imidazole; and 1- [2,4-difluoro-β-(n-decyIthio)phenethyl]imidazole. - 55 43267 EXAMPLE 16 1-[4-chloro-fi-(4'-chlorophenylthio)phenethyl]imidazole nitrate (1 g.) in 100 ml. of dichloromethane is shaken with excess dilute po.tassium carbonate solution until the salt is completely dissolved. The organic layer is then separated, washed with water and dried over magnesium sulfate.
Evaporation-of the solvent yields l-[4-chloro-f3-(4’-chloro· phenylthio)phenethyl]imidazole as a gum.
Ln similar manner, the acid addition salts of all compounds of Formula (I) can be converted to the corresponding compounds in base form, for example, 1-[2,4-dichloro-β-(3',41-dichlorophenylthio)phenethyl] imidazole; 1-[2,4-dichloro-β-(2 *, 4'-dichlorobenzylthio)phenethyl ]imidazole; 1-[2,4-dichloro-β-(n-heptylthio)phenethyl]imidazole: 1-(2,4-dichloro-6- {41 -chlorophenylthio) phenet,hy 1] imidazole .· 1- [2,4-dichloro-β-(4'-chlorobenzylthio)phenethyl]im idazole, and so forth. - 56 43267 EXAMPLE 17 Nitric acid (70%; d=1.42) is added dropwise to a stirred solution of 2.5 g. of 1-[4-chloro-p-(4'-chlorophenylthio) phenethyl]imidazole in 40 ml. anhydrous ether until precipitation is complete. The product is filtered off, washed with ether and dried. Recrystallization from ethyl acetate yields 1-[4-chloro-β-(4'-chlorophenylthio)phenethyl] imidazole nitrate, m.p. 136.5-137.5°C..
In similar manner, all compounds of Formula (I) in 10 base form can be converted to the acid addition salts by treatment in the conventional manner with the appropriate acid. - 57 • 43267 EXAMPLE 18 The anti-bacterial activity of certain compounds of the present invention and of Kef lin* is illustrated in the following procedure.
Streptococcus faecalis, a gram(+) bacteria, is cultured at 37°C. in Brain-Heart Infusion Broth (Difco).
After 24 hours the culture is diluted to a concentration o of 1x10 cells/ml. with the growth medium. Of this suspension, 0.05 ml. is added to various dilutions of the test compounds.
The test compounds are dissolved in dimethyl sulfoxide, ethanol or water at a concentration of 10 mg./ml. and thereafter diluted with sterile water to give a stock solution having a concentration of 100 ug./ml. From this stock solution, appropriate dilutions are made. Approximately ml. of each dilution is added to a sterile test tube and 0.05 ml. of the above prepared inoculum is then added 1 to each tube. Incubation is then carried out for 24 hours and the minimal inhibitory concentration (MIC), which is the concentration at which no visible growth occurs, is then determined. * sodium salt of 7-(thiophene-2-acetamido) cephalosporanic acid - 58 43267 Table X Compound Minimal Inhibitory Concentration ug./ml.
Keflin 1-[3,4-dichloro-β- (3', 4'-dichloro- 10 phenylthio)phenethyl)imidazole nitrate 1-[2,4-dichloro-β-(4'-chlorobenzyl- lU . thio)phenethyl]imidazole nitrate 1-[4~chloro-(3- (4 '-chlorophenylthio)- 3.3 phenethyl]imidazole nitrate - 59 43267 EXAMPLE 19 The anti-fungal activity of certain compounds of the present invention and of Miconazole* is illustrated in the following procedure.
Trichophyton rubrum is cultured on Sabourad Dextrose agar (Difco) at room temperature for 14 days. The fungi mat is then removed from the agar slant and homogenized to a fine suspension in Sabouraud Dextrose Broth. This suspension is diluted to a uniform concentration (OD of 0.1 at 600 nm) and 0.05 ml. is added to various dilutions of the test c.ompounds.
The test compounds are dissolved in dimethyl sulfoxide, ethanol or water at a concentration of 10 mg./ml. and thereafter diluted with sterile water to give a concentration of 100 pg/ml. From this stock solution appropriate dilutions were made. Approximately 4 ml. of each dilution is added to a sterile test tube and 0.05 ml. of the above prepared inoculum is then added to each tube Incubation is carried out for 7 to 14 days depending on the growth in the negative control.
The minimal inhibitory concentration (MIC), which is the concentration at which no visible growth occurs, is then determined for each test compound and for Miconazole.
The results obtained are listed in Table I. * 1- [2,4-dichloro- ti- (2',4‘-dichlorobenzyloxy)phenethyl) imidazole nitrate. -60 10 Table I Minimal Compound tration Inhibitory Concenpg./ml. Miconazole 10 1-[2,4-dichloro-β-(2', 4'-dichlorobenzylthio) phenethyl]imidazole nitrate 3 1- [2,4-dichloro-0-(4'-chlorobenzylthio)phenethyl]imidazole nitrate 3 1-[2,4-dichloro-B-(n-heptylthio)phenethyl] imidazole oxalate 3 - 61 43267 Example 20 The following formulations are typical of topical, oral and parenteral dosage forms for the compounds of the present invention: Cream: a compound of the present invention 1.0 g. stearic acid 10.0 g. Span 60 (Tradename for surfactant) commercial 5.2 g. Span 80 (Tradename for surfactant) commercial 1.0 g. propylene glycol 5.0 g. methyl paraben 0.05 g. propyl paraben 0.01 g. distilled water qs. to 100,0 g. The constituents are mixed at 60°C. and cooled with agitation to produce a smooth cream. Tablet: a compound of the present invention 100 mg. lactose USP 80 mg. cornstarch 16 mg. polyvinylpyrrolidone 5.6 mg. magnesium stearate 0.4 mg. 200.0 mg. The constituents are mixed and granulated with an appropriate solvent, e.g. methanol, dried, then formed into tablets using suitable tableting equipment. - Suppository: a compound of the present invention 0.1 g. polyethylene glycol 1000 1.0 g. polyethylene glycol 4000 0.1 g. 1.2 g - 62 43267 The constituents are mixed together at 50°C., then poured into molds and allowed to cool to room temperature.
Injectable Solution: a compound of the present invention 0.5 g 5 propylene glycol 30.0 g sodium chloride 0.8 g distilled water gs. to 100 ml.
A solution of the active compound hereof in the propylene glycol is mixed with the sodium chloride in water, brought to final volume, and filtered through 0.2μ membrane filter and packaged under sterile conditions.

Claims (40)

1. CLAIMS :1. A compound of the formula: and the acid addition salts thereof, wherein: R is alkyl, alkenyl, aralkenyl, substituted aralkenyl, alkynyl, cycloalkyl, cycloalkyl alkyl, aralkyl, substituted aralkyl, aryl or '· substituted aryl, said substituted aralkenyl and substituted aralkyl containing at least one substituent on the aryl moiety selected from the group consisting of halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro and cyano and said substituted aryl containing at least one substituent selected from the group consisting of halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro, amino, acylamino and cyano; R 1 is hydrogen, halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro, cyano, thiocyanato θ Γ. the group in which R is alkyl, cycloalkyl, aralkyl, substituted aralkyl, aryl on. substituted aryl, said substituted aralkyl and said substituted aryl containing at least one substituent on the aryl moiety selected from the group consisting of halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro and cyano; m, n and p are independently selected from the integers zero, 1 and 2; - 64 43267 1 provided that the value of m cannot be greater than the value of n except when R is aryl or substituted aryl.
2. A compound of Claim 1 wherein m is zero. 5
3. A compound of Claim 2 wherein R^ is halo and R is alkyl, alkenyl, aralkenyl, halo substituted aralkenyl, aralkyl, halo substituted aralkyl, aryl or halo substituted aryl.
4. A compound of Claim 3 wherein [1¾^] is mono halo or 10 dihalo and R is alkyl containing 1 to 12 carbon .atoms, 2-alkenyl, phenyl 2-alkenyl, chloro substituted phenyl 2-alkenyl, benzyl, chloro or fluoro substituted benzyl, phenyl or chloro substituted phenyl.
5. A compound of Claim 4 wherein ER 1 ] is 2,4-dichloro, Ir 2,4-dibromo or 2,4-difluoro.
6. The compound of Claim 5 which is 1-[2,4-dichloro-β(n-pentylthio)phenethyl]imidazole and the acid addition salts thereof.
7. The compound of Claim 5 which is 1-[2,4-dichloro-β20 (n-heptylthio)phenethyl]imidazole and the acid addition salts thereof. - 65 3267
8. The compound of Claim 5 which is 1-[2,4-dichloro-B(n-octylthio)phenethyl]imidazole and the acid addition salts thereof.
9. The compound of Claim 5 which is 1-[2,4-dichloro-P·' (n-nonylthio)phenethyl]imidazole and the acid addition salts thereof.
10. The compound of Claim 5 which is 1- [2,4-dichloro-f3(n-hexylthio)phenethyl]imidazole and the acid addition salts thereof.
11. - The compound of Claim 5 which is 1-[2,4-dibromo-f3(n-hexylthio)phenethyl]imidazole and the acid addition salts thereof.
12. The compound of Claim 5 which is l-[2,4-dibromo-8(n-heptylthio)phenethyl]imidazole and the acid addition salts thereof.
13. The compound of Claim 5 which is 1-[2,4-dibromo-f3(n-octylthio)phenethyl]imidazole and the acid addition salts thereof.
14. The compound of Claim 5 which is 1-[2,4-difluoro-(3(n-octylthio)phenethyl]imidazole and the acid addition salts thereof. - 66 43267
15. The compound of Claim 5 which is 1-[2,4-difluoro-f3(n-nonylthio)phenethyl]imidazole and the acid addition salts thereof.
16. The compound of Claim 5 which is 1-[2,4-dif luoro-[35 (n-decylthio)phenethyl]imidazole and the acid addition salts thereof.
17. The compound of Claim 5 which is l-[2,4-dichloro-B(2-ootenylthio)phenethyl]imidazole and the acid addition salts thereof. ]0 '
18. The compound of Claim 5 which is l-[2,4-dichloro-63-phenyl-2-propenylthio)phenethyl]imidazole and the acid addition salts thereof.
19.. The compound of Claim 5 which is 1- [2,4-dichloro-f3(3-(4'-ehlorophenyl)-2-propenylthio)phenethyl]imidazole 15 and the acid addition salts thereof, ,
20. The compound of Claim 5 which is 1-[2,4-dichloro-f3(4'-chlorobenzylthio)phenethyl]imidazole and the acid addition salts thereof..
21. The compound of Claim 5 which is l-[2,4-dichloro-f320 (4'-fluorobenzylthio)phenethyl]imidazole and the acid addition salts thereof. - 67
22. The compound of Claim 5 which is l-[2,4-dichloro-8(2',4'-dichlorobenzylthio)phenethyl]imidazole and the acid addition salts thereof.
23. The compound of Claim 5 which is l-[2,4-dichloro-8(3',4'-dichlorobfenzylthio)phenethyl]imidazole and the acid addition salts thereof.
24. The compound of Claim 5 which is l-[2,4-dibromo-6(4!-chlorobenzylthio)phenethyl]imidazole and the acid addition salts thereof.
25. The compound of Claim 5 which is 1-[2,4-dichloro-β-(4'-chloi phenylthio)phenethyl]imidazole and the acid addition salts thereof.
26. The compouhd of Claim 5 which is 1-[2,4-dichloro-8(3',4'-dichlorophenylthio)phenethyl]imidazole and the acid addition salts thereof.
27. The compound of Claim 5 which is 1~[2,4-dichloro-8(2',4'-dichlorophenylthio)phenethyl]imidazole and the acid addition salts thereof. > 68 43267
28. The compound of Claim 5 which is 1-[2,4-dichloro-8(3*,4',5'-trichlorophenylthio)phenethyl]imidazole and the acid addition salts thereof.
29. The compound of Claim 5 which is 1-[2,4-dibromo-fi5 (3’,4’-dichlorophenylthio)phenethyl]imidazole and the acid addition salts thereof. - 69 43267 30, A composition useful for inhibiting the growth of fungi or bacteria which comprises a compound of the formula: or an acid addition salt thereof, wherein: 5 R is alkyl, alkenyl, aralkenyl, substituted aralkenyl, alkynyl, cycloalkyl, cycloalkyl alkyl, aralkyl, substituted aralkyl, aryl or substituted aryl, said substituted aralkenyl and substituted aralkyl containing at least one substituent on the aryl mpiety selected from the group consisting of halo, 10 lower alkyl, lower alkoxy, trifluoromethyl, nitro and cyano and said substituted aryl containing at least one substituent selected from the group consisting of halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro, amino, acylamino and cyano?
R 1 is hydrogen, halo, lower alkyl, lower alkoxy, tri15 fluoromethyl, nitro, cyano, thiocyanato pr the group in which R is alkyl, cycloalkyl, aralkyl, substituted aralkyl, aryl substituted aryl, said substituted aralkyl and said substituted aryl containing at least one substituent on the aryl moiety selected from the group consisting of halo, 2o lower alkyl, lower alkoxy, trifluoromethyl, nitro and cyano; m, n and p are independently selected from the integers zero, 1 and 2; - 70 43367 provided that the value of m cannot be greater than the value of n except when
R is aryl or substituted aryl; in admixture with a suitable carrier. 5 31. The composition of Claim 30 for pharmaceutical use wherein the carrier is a pharmaceutically acceptable, non-toxic carrier.
32. The composition of Claim 31 wherein the compound of Formula (I) is present in an amount ranging between 0.1 10 and 10.0 weight percent of the composition.
33. A method of inhibiting the growth of fungi or bacteria which comprises applying to a host object containing, or subject to attack by, fungi or bacteria, a fungicidally or bacteriocidally effective amount of a compound of the 15 formula (I) or an acid addition salt thereof or a composition containing same as an active ingredient, wherein: - 71 432 67 R is alkyl, alkenyl, aralkenyl, substituted aralkenyl, alkynyl, eycloalkyl, eycloalkyl alkyl, aralkyl, substituted aralkyl, aryl -Or. substituted aryl, said substituted aralkenyl and substituted aralkyl containing at least one substituent 5 on the aryl moiety selected from the group consisting of halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro and cyano and said substituted aryl containing at least one substituent selected from the group consisting of halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro, amino, acylamino and cyano; 1 R^ is hydrogen, halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro, cyano, thiocyanato or ' the group in which R is alkyl, eycloalkyl, aralkyl, substituted aralkyl, aryl substituted aryl, said substituted aralkyl •and said substituted aryl containing at least one substituent on the aryl moiety selected from the group consisting of halo, lower alkyl; lower alkoxy, trifluoromethyl, nitro and cyano; m, n and p are independently selected from the integers zero, 1 and 2; provided that the value of m cannot be greater than the value of n except when is aryl or substituted aryl. - 72 43267
34. A process for the preparation of compounds of the formula: CH-CH S^ m V=/ Γ (I) and the acid addition salts thereof, wherein: R is alkyl, alkenyl, aralkenyl, substituted aralkenyl, 5 aikynyl, cycloaikyl, cycloaikyl alkyl, aralkyl, substituted aralkyl, aryl or . substituted aryl, said substituted aralkenyl and substituted aralkyl containing at least one substituent on the aryl moiety selected from the group consisting of halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro and cyano 10 and said substituted aryl containing at least one substituent selected from the group consisting of halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro, amino, aoylamino and cyano; R 1 is hydrogen, halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro, cyano, thiocyanato or : the group in which R is alkyl, cycloaikyl, aralkyl, substituted aralkyl, aryl or.·. substituted aryl, said substituted aralkyl and said substituted aryl containing at least one substituent on the aryl moiety selected from the group consisting of halo, lower 20. Alkyl, lower alkoxy, trifluoromethyl, nitro and cyano; m, n and p are independently selected from the integers zero, 1 and 2; - 73 43267 provided that the value of m cannot be greater than the value of n except when R xs aryl or substxtuted aryl; which comprises: a) condensing a compound of the formula (IX) wherein R^ and p are defined as above and X is a leaving group, with a compound of the formula RSH (III) wherein R is defined as above, to produce a 1-(β-(R-thio) phenethyl]imidazole of the formula wherein R, R^ and p are defined as above; or - 74 43267 b) oxidizing a compound of the formula 5 (I-A) wherein R, R^ and p are defined as above to produce a corresponding compound of the formula R (I-B,C) wherein R, R^ and p are defined as above and q is 1 or 2; or c) converting a compound of Formula (I) to an acid addition salt thereof or converting an acid addition salt of a compound of Formula (I) to a free base. - 75 ι
35. A compound of claim 1 or acid addition salt thereof as exemplified herein.
36. A method according to claim 33 as described herein.
37. A process for preparing a compound of claim 1 or an 5 acid addition salt thereof, as described herein.
38. A compound according to claim 1 or acid addition salt thereof when prepared by a process according to Claim 34 or claim 37.
39. An antifungal or antibacterial composition comprising 10 a compound according to any one of claims 2 to 29, 35 and 38.
40. An antifungal or antibacterial composition comprising a compound of Formula 1 as exemplified herein.
IE2061/75A 1974-09-23 1975-09-19 1-/ -(r-thio)phenethyl/imidazoles and derivatives thereof IE43267B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50838474A 1974-09-23 1974-09-23
US59362075A 1975-07-07 1975-07-07

Publications (2)

Publication Number Publication Date
IE43267L IE43267L (en) 1976-03-23
IE43267B1 true IE43267B1 (en) 1981-01-28

Family

ID=27056177

Family Applications (1)

Application Number Title Priority Date Filing Date
IE2061/75A IE43267B1 (en) 1974-09-23 1975-09-19 1-/ -(r-thio)phenethyl/imidazoles and derivatives thereof

Country Status (19)

Country Link
JP (1) JPS5910344B2 (en)
AR (1) AR224222A1 (en)
AU (1) AU496881B2 (en)
CA (1) CA1064040A (en)
CH (1) CH623813A5 (en)
DE (1) DE2541833A1 (en)
DK (1) DK155283C (en)
FI (1) FI64583C (en)
FR (1) FR2285126A1 (en)
GB (1) GB1485719A (en)
HK (1) HK8380A (en)
IE (1) IE43267B1 (en)
IL (1) IL47885A (en)
MX (1) MX4832E (en)
MY (1) MY8000270A (en)
NL (1) NL174462C (en)
NO (1) NO144345C (en)
SE (1) SE428471B (en)
YU (3) YU39746B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA755100B (en) * 1974-09-23 1977-03-30 Syntex Inc 1-(b-(r-thio) phenethyl) imidazoles and derivatives thereof
DE2963796D1 (en) * 1979-01-22 1982-11-11 Syntex Inc Imidazole derivatives, pharmaceutical compositions containing them and their preparation
JPS63156228U (en) * 1987-04-01 1988-10-13
DE3939525A1 (en) * 1989-11-30 1991-06-06 Hoechst Ag ARYL-ALKYL-AZOLES SUBSTITUTED WITH MULTIPLE UNSATURATED REMAINS, METHOD FOR THEIR PRODUCTION AND THEIR USE
IT1303672B1 (en) * 1998-07-28 2001-02-23 Nicox Sa NITRATED SALTS OF DRUGS ACTIVE IN BONE DISORDERS
CN116063234B (en) * 2022-12-29 2023-11-24 山东京卫制药有限公司 Preparation method of sulconazole nitrate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU557755A3 (en) * 1968-08-19 1977-05-05 Янссен Фармасьютика Н.В. (Фирма) Method for preparing imidazole derivatives
US3658813A (en) * 1970-01-13 1972-04-25 Janssen Pharmaceutica Nv 1-(beta-aryl-beta-(r-oxy)-ethyl)-imidazoles
DE2041771C3 (en) * 1970-08-22 1979-07-26 Bayer Ag, 5090 Leverkusen derivatives
SE364275B (en) * 1971-06-17 1974-02-18 Janssen Pharmaceutica Nv
DE2242454A1 (en) * 1972-08-29 1974-03-07 Bayer Ag 1-AETHYL-IMIDAZOLE, METHOD FOR MANUFACTURING IT AND ITS USE AS A MEDICINAL PRODUCT

Also Published As

Publication number Publication date
DE2541833A1 (en) 1976-04-01
YU226981A (en) 1982-02-28
SE7510595L (en) 1976-03-24
MY8000270A (en) 1980-12-31
NO144345B (en) 1981-05-04
AU8408175A (en) 1977-02-24
JPS5157828A (en) 1976-05-20
DK155283B (en) 1989-03-20
JPS5910344B2 (en) 1984-03-08
YU39746B (en) 1985-04-30
GB1485719A (en) 1977-09-14
CH623813A5 (en) 1981-06-30
NO753048L (en) 1976-03-24
FR2285126A1 (en) 1976-04-16
SE428471B (en) 1983-07-04
HK8380A (en) 1980-03-14
NL174462B (en) 1984-01-16
IL47885A0 (en) 1975-11-25
IE43267L (en) 1976-03-23
YU227081A (en) 1982-02-28
MX4832E (en) 1982-10-26
DK155283C (en) 1989-07-24
DK427075A (en) 1976-03-24
AR224222A1 (en) 1981-11-13
NL7510224A (en) 1976-03-25
FI752614A (en) 1976-03-24
NL174462C (en) 1984-06-18
CA1064040A (en) 1979-10-09
IL47885A (en) 1979-01-31
YU224475A (en) 1982-02-28
AU496881B2 (en) 1978-11-09
FR2285126B1 (en) 1979-09-14
FI64583C (en) 1983-12-12
NO144345C (en) 1981-08-12
FI64583B (en) 1983-08-31
DE2541833C2 (en) 1989-09-14

Similar Documents

Publication Publication Date Title
US4078071A (en) Derivatives of substituted N-alkyl imidazoles
US4036970A (en) Imidazol-1-yl propane derivatives
US4123542A (en) Derivatives of N-alkyl imidazoles
US4055652A (en) 1-[β(R-thio)phenethyl]imidazoles and derivatives thereof
JPH03169879A (en) Azolylmethyloxylane and bactericidal agent containing said compound
JPS609030B2 (en) Method for producing quaternary imidazolium salt
US4045568A (en) Derivatives of substituted N-alkyl imidazoles
US4059705A (en) Derivatives of substituted n-alkyl imidazoles
IE43267B1 (en) 1-/ -(r-thio)phenethyl/imidazoles and derivatives thereof
US4210656A (en) Imidazolyl vinyl ethers and process for preparing same
JPS6028820B2 (en) Substituted N-alkylimidazole derivatives
US4036974A (en) 1-{2&#39;-[R&#39;-Thio(oxy)]-3&#39;-(R2 -thio(oxy)]propyl}imidazoles
US4038409A (en) 1-phenethylimidazoles
US4036973A (en) Imidazol-1-yl propane derivatives
US4036975A (en) 1-[2-(1-Adamantyl)-2-(R-thio)ethyl]imidazoles and 1-[2-(1-adamantyl)-2-(R-oxy)ethyl]imidazoles
US4375474A (en) Dioxalane containing imidazole compounds, compositions and use
DE3121676A1 (en) &#34;1,1-DIARYL-2-AZOLYL-AETHANE, THEIR PRODUCTION, THEIR USE AND THE PREPARATIONS CONTAINING THESE COMPOUNDS&#34;
CA1166260A (en) 1-phenetylimidazole derivatives
US4039677A (en) Novel 1-phenethylimidazoles
IE52055B1 (en) New ethenylimidazole derivatives,processes for their preparation and pharmaceutical compositions containing them:intermediates,useful in their preparation and a process for the preparation thereof
JPS635388B2 (en)
KR790001843B1 (en) Process for producing 1-( -(r-thio)phenehtyl) imidazol and derivatives thereof
US4272545A (en) Derivatives of thienyl- and furyl-substituted N-butyl and N-phenyl imidazoles
JPS5845428B2 (en) Compounds that inhibit the growth of fungi or bacteria
JPS6234758B2 (en)